ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma.

doi:10.1158/0008-5472.CAN-22-1826

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma.

Cancer research - 4 Apr 2023

Eichhoff Ossia M, Stoffel Corinne I, Käsler Jan, Briker Luzia, Turko Patrick, Karsai Gergely, Zila Nina, Paulitschke Verena, Cheng Phil F, Leitner Alexander, Bileck Andrea, Zamboni Nicola, Irmisch Anja, Balazs Zsolt, Tastanova Aizhan, Pascoal Susana, Johansen Pål, Wegmann Rebekka, Mena Julien, Othman Alaa, Viswanathan Vasanthi S, Wenzina Judith, Aloia Andrea, Saltari Annalisa, Dzung Andreas, Krauthammer Michael, Schreiber Stuart L, Hornemann Thorsten, Distel Martin, Snijder Berend, Dummer Reinhard, Levesque Mitchell P

Abstract excerpt

Clinical management of melanomas with NRAS mutations is challenging. Targeting MAPK signaling is only beneficial to a small subset of patients due to resistance that arises through genetic, transcriptional, and metabolic adaptation. Identification of targetable vulnerabilities in NRAS-mutated melanoma could help improve patient treatment. Here, we used multiomics analyses to reveal that NRAS-mutated melanoma...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to GTP Phosphohydrolases

Share to Melanoma

Share to Mitogen-Activated Protein Kinase Kinases

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Reactive Oxygen Species

Share to Skin Neoplasms

Source

Open in PubMed

Identifiers

PMID: 36946761
DOI: 10.1158/0008-5472.CAN-22-1826

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma.PMID 36946761Read ↗

ROS induction as a strategy to target persister cancer cells with low metabolic activity in NRAS mutated melanomaSemantic proximity Read ↗

Metabolic rewiring in melanoma.Semantic proximity Read ↗

Targeting PHGDH Upregulation Reduces Glutathione Levels and Resensitizes Resistant NRAS-Mutant Melanoma to MAPK Kinase Inhibition.Semantic proximity Read ↗

Understanding Molecular Mechanisms of Phenotype Switching and Crosstalk with TME to Reveal New Vulnerabilities of Melanoma.Semantic proximity Read ↗

Melanoma Metabolism: Molecular Mechanisms and Therapeutic Implications in Cutaneous OncologySemantic proximity Read ↗

Metabolic Alterations and Therapeutic Opportunities in Rare Forms of Melanoma.Semantic proximity Read ↗

Clonal dynamics shaped by diverse drug-tolerant persister states in melanoma resistanceSemantic proximity Read ↗

Genomic subtypes of cutaneous melanoma have distinct metabolic profiles: A single-cell transcriptomic analysis.Semantic proximity Read ↗

Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanomaSemantic proximity Read ↗

Metabolic rewiring in melanoma drug-resistant cells.Semantic proximity Read ↗

NAMPT Over-Expression Recapitulates the BRAF Inhibitor Resistant Phenotype Plasticity in MelanomaSemantic proximity Read ↗

Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.